Nevertheless, since a relevant number of CRC cases exhibit oncogenic Kras mutations (16), the combination of HSP90 inhibition with radiotherapy seems particularly interesting for this subgroup of patients. The gene discussed is KRAS; the disease is colorectal carcinoma.